Table 4.

Fold Change in EC50s With RAS Y93H for Approved NS5A Inhibitors

NS5A Inhibitor	Fold-change in vitro1
	GT1a	GT1b	GT2	GT3	GT4
Daclatasvir	1400–5432	12–145	749–1750	2154–3733	45–169
Elbasvir	220–600	12-67	ND	157	7.5
Ledipasvir	1677–3309	1319–1807	ND	30	1000
Ombitasvir	41,383	77	4710	6728	20–100
Pibrentasvir	7	0.6	ND	2.5	ND
Velpatasvir	609	3	46	724	3

Note: data are according to ref 80

¹Y93H fold change value in comparison with wild-type strains; maximum and minimum values are reported.

For first-generation NS5A-inhibitors, RASs with more than 100-fold changes are shown in red (resistance likely); RASs with 20–100-fold changes are reported in blue (resistance possible); RASs with 3–20-fold changes are reported in green (likely susceptible). For second-generation NS5A-inhibitors, such as elbasvir and velpatasvir, RASs with more than 10-fold chnages are reported in red (resistance likely); RASs with 3–9-fold changes are reported in blue (resistance possible); RASs with less than 2.5-fold changes are reported in green (likely susceptible);

GT, genotype; ND, no data available; EC50, effective concentration for 50% inhibition